Teal Health Raises $22 Million in Series A Funding Led by .406 Ventures

Teal Health, the creators of Teal Wand™, the first FDA-authorized at-home HPV cervical cancer screening device, has secured $22 million in Series A funding to meet increasing consumer demand and expand access. The funding round, led by .406 Ventures, also saw continued support from Emerson Collective (managed by Yosemite), Forerunner, and Serena Ventures, with the addition of new participation from Japan-based MPower Partners. This investment brings Teal Health's total funding to $45 million and comes at a time when nearly one in three U.S. women is not up to date on screening, primarily due to limited appointment availability caused by physician shortages, making traditional in-office screening inaccessible.

The company aims to address this issue by providing a convenient at-home screening alternative. The new capital will be utilized to establish a network of partnerships with payors, health systems, employers, providers, and brands to make screening widely available. Teal Health also plans to expand direct-purchase options for individuals and organizations. Moreover, the funding will support the company's expansion by hiring across key clinical, commercial, technology, and operational functions. Teal Health CEO and Co-Founder, Kara Egan, emphasized the importance of providing an accurate and convenient screening alternative, stating that the funding will enable the company to scale to meet the demand of patients and providers.

The Teal Wand, the first FDA-authorized self-collection device for at-home HPV cervical cancer screening, eliminates the need for a speculum or in-office visit, and the company pairs the at-home sample collection with a telehealth visit, delivering results through a secure platform. The company's aim is to make at-home screening a routine and widely available part of preventive care nationwide. With insurance coverage set to expand in 2027, Teal Health is poised to revolutionize how millions of women receive essential preventive healthcare.

Teal Health has already screened thousands of women nationally since receiving FDA authorization in 2025 and is making significant strides in advancing research on self-collection screening. The company's ultimate goal is to eliminate cervical cancer by making screening accessible, comfortable, and accurate.